162 related articles for article (PubMed ID: 38071928)
1. Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.
Liang K; Feliciano JL; Marrone KA; Murray JC; Hann CL; Anagnostou V; Tackett SA; Shin EJ; Hales RK; Voong KR; Battafarano RJ; Yang SC; Broderick SR; Ha JS; Forde PM; Brahmer JR; Lam VK
ESMO Open; 2024 Jan; 9(1):102199. PubMed ID: 38071928
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
3. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
Nakayama I; Takahari D; Chin K; Wakatsuki T; Takamatsu M; Yamamoto N; Ogura M; Ooki A; Fukuda K; Osumi H; Fukuoka S; Shinozaki E; Yamaguchi K
ESMO Open; 2023 Aug; 8(4):101582. PubMed ID: 37348349
[TBL] [Abstract][Full Text] [Related]
4. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
Jin Z; Holubek M; Sukov WR; Sattler CA; Wiktor AE; Jenkins RB; Wu TT; Yoon HH
Am J Clin Oncol; 2019 Feb; 42(2):190-195. PubMed ID: 30516569
[TBL] [Abstract][Full Text] [Related]
5. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
7. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases.
Harada K; Hwang H; Wang X; Abdelhakeem A; Iwatsuki M; Murphy MAB; Maru DM; Weston B; Lee JH; Rogers JE; Trail A; Shanbhag N; Zhao M; Bhutani MS; Nguyen QN; Swisher SG; Ikoma N; Das P; Hofstetter WL; Badgwell BD; Ajani JA
Gastric Cancer; 2020 Sep; 23(5):904-912. PubMed ID: 32347396
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
Yoon HH; Lewis MA; Foster NR; Sukov WR; Khan M; Sattler CA; Wiktor AE; Wu TT; Jenkins RB; Sinicrope FA
Int J Cancer; 2016 Oct; 139(7):1626-31. PubMed ID: 27198655
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma.
Tsai C; Nguyen B; Luthra A; Chou JF; Feder L; Tang LH; Strong VE; Molena D; Jones DR; Coit DG; Ilson DH; Ku GY; Cowzer D; Cadley J; Capanu M; Schultz N; Beal K; Moss NS; Janjigian YY; Maron SB
JAMA Netw Open; 2022 Aug; 5(8):e2228083. PubMed ID: 36001319
[TBL] [Abstract][Full Text] [Related]
11. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
Janjigian YY; Werner D; Pauligk C; Steinmetz K; Kelsen DP; Jäger E; Altmannsberger HM; Robinson E; Tafe LJ; Tang LH; Shah MA; Al-Batran SE
Ann Oncol; 2012 Oct; 23(10):2656-2662. PubMed ID: 22689179
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Kim BJ; Jee HJ; Rha SY; Han HS; Ryu MH; Park SH; Kim JG; Bae WK; Lee KW; Oh DY; Byun JH; Kim DS; Suh YJ; An H; Zang DY
Gastric Cancer; 2022 May; 25(3):609-618. PubMed ID: 35015188
[TBL] [Abstract][Full Text] [Related]
16. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Cinar P; Calkins SM; Venook AP; Kelley RK
Anticancer Res; 2014 Dec; 34(12):7357-60. PubMed ID: 25503172
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
18. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
[TBL] [Abstract][Full Text] [Related]
19. Targeting the human epidermal growth factor receptor 2 in esophageal cancer.
Almhanna K; Meredith KL; Hoffe SE; Shridhar R; Coppola D
Cancer Control; 2013 Apr; 20(2):111-6. PubMed ID: 23571701
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
